SCA
SRPT icon

Secor Capital Advisors’s Sarepta Therapeutics SRPT Stock Holding History

Secor Capital Advisors’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-9,395
Closed -$317K – 531
2017
Q2 		$317K Sell
9,395
-14,687
-61% -$478K 0.03% 392
2017
Q1 		$713K Buy
+24,082
New +$745K 0.08% 296

Other funds holding SRPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
TCP
Tourbillon Capital Partners New York $6.26M AUM 42.29% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Secor Capital Advisors's SRPT Position: Q3 2017 in Review

Secor Capital Advisors sold out of Sarepta Therapeutics (SRPT) in Q3 2017, closing a stake of 9,395 shares — an estimated $317K sold.

Secor Capital Advisors first reported a position in SRPT in Q1 2017 and held it in 2 quarters. The position peaked at $713K in Q1 2017. 233 funds tracked by Wall St. Rank hold SRPT as of Q3 2017.

  • Secor Capital Advisors reported no remaining Sarepta Therapeutics position as of Q3 2017 after selling out during the quarter.
  • Secor Capital Advisors sold 9,395 Sarepta Therapeutics shares in Q3 2017, an estimated $317K.
  • Secor Capital Advisors first reported a position in Sarepta Therapeutics in Q1 2017 and held it in 2 quarters.
  • Secor Capital Advisors's Sarepta Therapeutics position peaked at $713K in Q1 2017.
  • 233 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2017.

Based on Secor Capital Advisors's 13F filing for Q3 2017, filed 14 Nov 2017.